awmsg logo



tipranavir (Aptivus®)


Reference No. 819

Publication date:
03/02/2011


Appraisal information

tipranavir (Aptivus®) 100 mg/ml oral solution


Company: Boehringer Ingelheim Ltd
BNF category: Infections
NMG meeting date: 17/11/2010
AWMSG meeting date: 15/12/2010
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2110
Ministerial ratification: 27/01/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tipranavir (Aptivus®) oral solution, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for combination antiretroviral treatment of HIV-1 infection in highly pre-treated children from 2 to 12 years of age with virus resistant to multiple protease inhibitors. Tipranavir (Aptivus®) should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options. Tipranavir (Aptivus®) oral solution is not suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download